HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Cryofocus Medtech (Shanghai) - The Industry, the Business and the Concerns

Pre-IPO Best Wellness Innovation Group - Here Are the Concerns

China Resources Medical - Hard to Earn High Profits Due to Poor Business Model and Policy Risk

Alibaba Health Information Technology (241.HK) - It’s Not Easy to Break a Deadlock

Ping An Healthcare and Technology (1833.HK) - Untenable Business Model Worsen the Logic and Outlook

Medlive Technology (2192.HK) - The Logic Has Shaken

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Huayiwang Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/huayiwang-technology-inc" target="_blank" data-smartkarma-citation="entities:35518:1" rel="noopener">Huayiwang Technology (1985554D HK)</a> is strong in its digital medical education solutions, which is the cornerstone business for the continuous expansion of other solution offerings and ecosystem.</li>
<li>HUAYIWANG charges service fees mainly from pharmaceutical companies, which could be a more sustainable profit model than charging from patients directly.</li>
<li>However, the increasing competition and potential risk of losing medical professionals could shake the foundations of HUAYIWANG's business. </li>
</ul>



Huayiwang Technology (1985554D HK) is strong in its digital medical education solutions, which is the cornerstone business for the continuous expansion of other solution offerings and ecosystem.
HUAYIWANG charges service fees mainly from pharmaceutical companies, which could be a more sustainable profit model than charging from patients directly.
However, the increasing competition and potential risk of losing medical professionals could shake the foundations of HUAYIWANG's business. 


Ping An Healthcare and Technology (1833 HK)

Pre-IPO Huayiwang Technology - The Business Model Is Reasonable, but There Are Also Challenges